River Global Investors LLP Has $1.29 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE)

River Global Investors LLP cut its position in shares of Kenvue Inc. (NYSE:KVUE) by 73.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,049 shares of the company’s stock after selling 163,521 shares during the quarter. River Global Investors LLP’s holdings in Kenvue were worth $1,293,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Empirical Finance LLC bought a new position in Kenvue during the third quarter worth about $336,000. UniSuper Management Pty Ltd bought a new position in Kenvue during the third quarter worth about $35,544,000. Citizens Business Bank bought a new position in Kenvue during the third quarter worth about $2,507,000. Fifth Third Bancorp lifted its stake in Kenvue by 35.3% during the fourth quarter. Fifth Third Bancorp now owns 277,580 shares of the company’s stock worth $5,976,000 after purchasing an additional 72,435 shares during the period. Finally, Clearbridge Investments LLC lifted its stake in Kenvue by 364.6% during the third quarter. Clearbridge Investments LLC now owns 484,321 shares of the company’s stock worth $9,725,000 after purchasing an additional 380,071 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of Kenvue stock traded up $0.08 during midday trading on Friday, reaching $19.20. The company had a trading volume of 15,941,057 shares, compared to its average volume of 15,351,688. The stock has a fifty day simple moving average of $19.82 and a 200 day simple moving average of $20.12. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. Kenvue Inc. has a 1-year low of $17.82 and a 1-year high of $27.80.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.78 billion. The business’s quarterly revenue was down 2.7% compared to the same quarter last year. Equities research analysts expect that Kenvue Inc. will post 1.15 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 4.17%. The ex-dividend date is Tuesday, May 7th.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on KVUE. Sanford C. Bernstein assumed coverage on shares of Kenvue in a research note on Thursday, April 11th. They set an “underperform” rating and a $18.00 price target for the company. JPMorgan Chase & Co. cut their target price on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. The Goldman Sachs Group assumed coverage on shares of Kenvue in a research note on Friday, March 1st. They issued a “neutral” rating and a $20.00 target price for the company. William Blair assumed coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They issued a “market perform” rating for the company. Finally, Royal Bank of Canada cut their target price on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $24.85.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.